Corporate Finance

Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics sectors.

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

WCVB Channel 5 News aired a segement with Immunovias IMMray® PanCan-d for early detection of pancreatic cancer on May 2nd 2019. Click here to watch the video.

Vator Securities advises Empros Pharma on 40 MSEK private placement

4 July 2019

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

Vator Securities Sole Bookrunner in Nanoform SEK 106 million private placement

3 July 2019

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

Vator Securities advises Xbrane Biopharma on 238 MSEK Directed and Rights Issue

2 June 2019

The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.

Xlucane Product Launch Insight with STADA and Xbrane Biopharma

12 April 2019

Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.

More News